ArticleEye (London, England)2026
Three-year outcomes of polypoidal choroidal vasculopathy according to polypoidal regression on optical coherence tomography angiography.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Management of polypoidal choroidal vasculopathy: Malaysian Consensus Guideline 2023.International journal of ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the 3-year outcomes of polypoidal choroidal vasculopathy (PCV) according to early polypoidal regression on swept-source optical coherence tomography angiography (SS-OCTA).
methodsThe medical records of 48 polypoidal lesions from 29 eyes of 29 patients diagnosed with PCV with a follow-up ≥3 years were retrospectively reviewed. Patients were divided according to SS-OCTA-defined polypoidal regression 3 months after the initial treatment into the regressed and persistent group. SS-OCTA images were analysed for microvascular and structural changes associated with early complete polypoidal regression.
resultsCompared with the persistent group, the regressed group (20 eyes), had better best-corrected visual acuity (BCVA) at 1 and 3 years (p = 0.000, p = 0.026, respectively) and less patients diagnosed with systemic hypertension (p = 0.043). The number of persistent polypoidal lesions 3 months after the initial treatment was significantly correlated with BCVA at 1 and 3 years (r = 0.498 p = 0.006 and r = 0.397 p = 0.033, respectively). Age, hypertension, number of persistent polypoidal lesions observed 3 months after initial treatment, and the baseline subfoveal choroidal thickness were also associated with the BCVA at 3 years after treatment. Early complete polypoidal regression was associated with a smaller hyperreflective lesion area within pigment epithelial detachment (PED) (p = 0.047, p = 0.024) and more flow signals in hyperreflective lesions (p = 0.047).
conclusionsEyes with early polypoidal regression showed better long-term visual outcomes than those with persistent polypoidal lesions. A smaller hyperreflective lesion area within the PED and more flow signals in the hyperreflective lesions could be considered favourable characteristics for early complete polypoidal regression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.